{"id":"W4406944849","doi":"10.1093/ofid/ofae631.774","title":"P-576. Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study","year":2025,"lang":"en","type":"review","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver Infectious Diseases Centre; GlaxoSmithKline (Canada)","funders":"","keywords":"Dolutegravir; Medicine; Human immunodeficiency virus (HIV); Lamivudine; Regimen; Virology; Rilpivirine; Family medicine; Pediatrics; Antiretroviral therapy; Internal medicine; Viral load; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002360845,0.0001472842,0.000226073,0.001586163,0.001298271,0.001219963,0.0006253151,0.0002304237,0.002422218],"category_scores_gemma":[0.01219999,0.0001550909,0.0003465802,0.003483088,0.0004559463,0.0004442095,0.0006097119,0.0002700573,0.000280305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01034744,"about_ca_system_score_gemma":0.01765381,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8234659,"about_ca_topic_score_gemma":0.9141709,"domain_scores_codex":[0.9978886,0.0005338494,0.0002474069,0.0001671133,0.0009041496,0.0002588027],"domain_scores_gemma":[0.9810749,0.003422961,0.005889388,0.0005131628,0.00724405,0.001855484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006951861,0.0003269191,0.9094811,0.001010482,0.0001065137,0.0006662147,0.005586417,0.0002191152,0.0006860655,0.0001304766,0.00725258,0.07383901],"study_design_scores_gemma":[0.00005769864,0.0003862134,0.9878718,0.0001788299,0.00007617361,0.0002587884,0.003685282,0.000306416,0.0003485499,0.00002238323,0.006783801,0.0000240696],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.9712167,0.00282561,0.00035809,0.0007103034,0.00002640089,0.001153124,0.01810663,0.00005267019,0.005550567],"genre_scores_gemma":[0.9914346,0.001625975,0.0008917261,0.0002736733,0.00001967854,0.0002169723,0.003738162,0.00001286456,0.00178635],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.1765341,"threshold_uncertainty_score":0.3551474,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01798693368333191,"score_gpt":0.3066840443462142,"score_spread":0.2886971106628823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}